Iran Flu Diagnostic And Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

The Iran flu diagnostic and treatment market is projected to grow at a CAGR of 5.36% throughout the forecast period and reach a market value of US$324.156 million by 2027. The market was valued at US$224.897 million in 2020.

The country is expected to grow at such a rate owing to the growing adoption of more advanced treatments and better equipment as the country has witnessed an increasing number of deaths. The adoption of more advanced equipment in the healthcare sector to curb the rising intensity of seasonal flu and an increasing number of deaths due to the same will drive the market in the coming years.

Increasing fatalities and hospital admissions due to influenza

According to the Ministry of Health, the number of deaths also increased during the last flu season from December 2018 to December 2019. Furthermore, during the same period, the number of hospitalizations also increased due to the growing incidence of the disease throughout the country, which is also one of the key factors bolstering the demand for diagnostic and treatment services in the country and amplifying the growth of the market significantly. Thus, looking at such statistics, the country is focusing on bringing in new and advanced technology to fight the consequences of the flu, wherein, major investments are being made.

Government investments in healthcare

The healthcare sector in Iran is dominated by a government presence, which has planned to modernize the ageing infrastructure of the sector in the coming years. Moreover, in 2017, the Ministry of Health and Medical Education, also forecasted that an investment of US$17 billion is expected in the healthcare sector during the next five years. This in turn is also projected to fuel the flu diagnostic and treatment market growth in Iran over the forecast period and beyond.

Increased investments in the healthcare sector

The growing investments in healthcare to update the knowledge of the current staff, hire more staff, develop more hospitals and healthcare institutions, and successfully add advanced technology into the healthcare sector will also bolster market growth in the coming years. According to a report published by the World Bank Group, the healthcare expenditure of Iran has increased significantly in the last few years, going from 5.994% (%of GDP) in 2013 to 8.103% (% of GDP) in 2016. This will further fuel the flu diagnostics and treatment market in the country in the coming years.

Iran flu diagnostic and treatment market has been segmented based on the type of flu, offering, age group, and end-user. Based on the type of flu, the market has been classified into type A and type B. By offering, the market has been segmented into diagnostics and therapeutics. By age group, the market has been segmented based on 0-14 years, 15-64 years, and >=65 years. By the end-user, the segmentation has been done based on the hospital laboratory, outpatient clinic, and reference laboratory.

Key Developments

• April 2020:  Shahid Beheshti University of Medical Sciences announced the clinical trials of testing the effectiveness of favipiravir or Avigan on patients infected with the coronavirus. Favipiravir is a drug developed in Japan for the treatment of new types of Influenza. Over 70 countries confirmed their contribution to the trial began at Masih Daneshwari hospital in Tehran.
• May 2021: Iran’s Food and Drug Administration (IFDA) announced that the domestic production of Iran’s influenza vaccines will meet a major part of Iran’s demand by next winter. A significant portion of flu vaccines will be provided by the domestic pharmaceutical companies in the country.

COVID-19 Impact on the Iran Flu Diagnostic and Treatment Market

The COVID-19 pandemic led to a significant decrease in industrial and commercial activities, due to the implementation of strict lockdown and social distancing regulations. This led to a decrease in the spread of influenza and flu-based diseases in the region. According to a report by the WHO, Iran recorded a decrease in influenza and flu cases in March 2020. This also led to a decrease in flu diagnosis and treatment. However, according to an update by the WHO, influenza cases in the region had a positivity rate of about 17% between week 27 of 2021 and week 4 of 2022 (Start of July to the end of January). This increase in influenza prevalence is expected to drive the flu diagnostic and treatment market. Moreover, as countries have started to resume activities in major sectors, influenza cases might increase rapidly. Hence, the market demand is expected to increase significantly.

Iran Flu Diagnostic and Treatment Market Scope:

Segmentation

• By Type of Flu
  • Type A
  • Type B
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • Others
  • Therapeutics
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By End-User
  • Hospital Laboratory
  • Outpatient Clinic
  • Reference Laboratory